Drug for celiac disease shows promise in treating severe post-COVID syndrome in children

In a small trial, Mass General Brigham researchers have found that a drug designed to treat celiac disease supported a more rapid return to normal activities for patients following COVID.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup